SAB Biotherapeutics (NASDAQ:SABS) Given Buy Rating at Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating restated by stock analysts at Chardan Capital in a report issued on Thursday,Benzinga reports. They presently have a $12.00 target price on the stock. Chardan Capital’s price objective indicates a potential upside of 203.03% from the stock’s previous close.

Several other equities analysts have also recently commented on SABS. Leerink Partners began coverage on shares of SAB Biotherapeutics in a research report on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price target for the company. Leerink Partnrs upgraded shares of SAB Biotherapeutics to a “strong-buy” rating in a research note on Wednesday, September 17th. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, SAB Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $9.33.

SAB Biotherapeutics Stock Performance

NASDAQ SABS opened at $3.96 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50. The company has a market cap of $188.54 million, a P/E ratio of -1.28 and a beta of 0.58. The stock has a 50-day moving average of $3.34 and a two-hundred day moving average of $2.56. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.38. As a group, analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SABS. ADAR1 Capital Management LLC purchased a new position in shares of SAB Biotherapeutics during the third quarter worth about $30,000. Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics during the 3rd quarter worth approximately $32,000. Virtu Financial LLC purchased a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $40,000. HB Wealth Management LLC acquired a new position in shares of SAB Biotherapeutics in the third quarter valued at approximately $618,000. Finally, Woodline Partners LP acquired a new stake in shares of SAB Biotherapeutics during the third quarter worth $5,730,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.